ArticleBMC neurology2026
Genome-wide association analysis of treatment response to onabotulinumtoxinA in Han Chinese patients with chronic migraine: a pilot study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND/
objectivesOnabotulinumtoxinA (BoNT-A) use is an established preventive treatment for chronic migraine (CM); however, individual response rates vary. Although genetic factors may contribute to this variability, the underlying genetic determinants remain largely undefined, especially in Asian populations. Therefore, we aimed to identify genetic variants associated with the response to BoNT-A treatment in Han Chinese patients with CM.
methodsWe conducted a genome-wide quantitative trait locus (QTL) analysis using the Taiwan Precision Medicine (TPM) array in Han Chinese patients with CM receiving BoNT-A treatment according to the PREEMPT protocol. Treatment efficacy was assessed by calculating the improvement in monthly headache days after 24 weeks compared with baseline. Genotype–phenotype associations were assessed using a linear regression model adjusted for relevant clinical covariates. Functional annotation, Gene Ontology (GO) annotation, and linkage disequilibrium (LD) mapping were performed to interpret the biological importance of significant variants.
resultsWe identified four intronic single nucleotide polymorphisms (SNPs) that showed genome-wide significance: rs11147666 in TRPC4, rs3924647 in LINC02197, rs56381512 in GTF2H2, and rs13126813 in SPOCK3. rs11147666 in TRPC4 showed the strongest association with treatment response. Patients with heterozygous variants showed lower improvement rates than those with common homozygotes. The implicated genes function in calcium ion transport, transcriptional regulation, and extracellular matrix interactions. Given the modest sample size and low minor allele frequencies, these findings should be interpreted as exploratory signals.
conclusionThis pilot genome-wide association study identified genetic variants linked to variability in BoNT-A response among Han Chinese patients with chronic migraine, highlighting potential candidate loci for future validation. Given the limited sample size and absence of an independent replication cohort, the reported loci should be interpreted as exploratory and hypothesis-generating findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.